National Bank of Canada’s Abeona Therapeutics ABEO Stock Holding History

National Bank of Canada’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.24M	Buy	+500,000	New	+$2.5M	﹤0.01%	1059

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

National Bank of Canada's ABEO Position: Q1 2026 in Review

National Bank of Canada opened a new position in Abeona Therapeutics (ABEO) in Q1 2026: 500,000 shares worth $2.24M. The stake represents ﹤0.01% of the portfolio and ranks #1059 among its holdings.

108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

National Bank of Canada held 500,000 shares of Abeona Therapeutics worth $2.24M as of Q1 2026.
Abeona Therapeutics was a new National Bank of Canada position in Q1 2026.
Abeona Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #1059 holding.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.